A sequential targeting nanoplatform for anaplastic thyroid carcinoma theranostics

Area of Science:

• Nanotechnology
• Biomedical Engineering
• Oncology

Background:

• Anaplastic thyroid carcinoma (ATC) is highly aggressive, lacking effective treatments and early diagnostic strategies.
• Efficient nanoparticle accumulation in tumors is crucial for nanotechnology-based cancer theranostics.

Purpose of the Study:

• To engineer a multifunctional sequential targeting nanoplatform for anaplastic thyroid carcinoma (ATC) theranostics.
• To achieve synergistic antiangiogenic photothermal therapy (PTT) and multimodal imaging-guided diagnosis.

Main Methods:

• Conjugated bevacizumab to polymer nanoparticles (NPs) for vascular endothelial growth factor (VEGF) targeting.
• Encapsulated IR825 as a photothermal agent with mitochondrial targeting for enhanced hyperthermia.
• Utilized the NPs as contrast agents for photoacoustic, ultrasound, and fluorescence imaging.

Main Results:

• The nanoplatform demonstrated effective accumulation in tumor regions.
• Sequential targeting combined with antiangiogenic PTT significantly enhanced tumor eradication efficacy.
• The NPs provided multimodal imaging capabilities for diagnosis and therapeutic monitoring.

Conclusions:

• The developed nanoplatform offers a promising theranostic strategy for aggressive ATC.
• Sequential targeting overcomes limitations of traditional approaches, leading to complete tumor eradication with minimal side effects.
• This strategy advances theranostic applications for ATC detection and therapy.